ArticleAmerican journal of translational research2026
Insulin plus metformin for gestational diabetes mellitus: impacts on blood glucose, coagulation function, and pregnancy outcomes.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective study focused on the impacts of insulin plus metformin (MET) on blood glucose (BG), coagulation function, and pregnancy outcomes in patients with gestational diabetes mellitus (GDM).
methodsThe subjects were 129 GDM patients visiting The First Affiliated Hospital of Air Force Medical University, including 60 patients receiving insulin aspart (IA; control group) and 69 cases given MET+insulin aspart (observation group). General information and treatment outcomes were compared. Pre- and post-treatment BG (fasting plasma glucose [FPG], 2-hour postprandial plasma glucose [2hPG], glycosylated hemoglobin [HbA1c]), islet function (fasting insulin [FINS], Homeostasis Model Assessment-Insulin Resistance Index (HOMA-IR), HOMA-Beta Cell Function Index [HOMA-β]), coagulation function (activated partial thromboplastin time [APTT], prothrombin time [PT], thrombin time [TT]), adverse drug reactions, pregnancy outcomes, and fetal and neonatal conditions were compared between the two groups. Efficacy determinants were analyzed using univariate and multivariate methods.
resultsCompared to controls, MET+IA-treated patients showed superior curative effects, lower post-treatment BG indexes, FINS, and HOMA-IR, higher HOMA-β and various coagulation function parameters, as well as reduced rates of overall adverse pregnancy outcomes, total neonatal adverse events, and macrosomia. The groups were comparable in the adverse drug reaction rate. An abortion history increased the risk of ineffective treatment.
conclusionInsulin+MET benefits BG control, coagulation function, and pregnancy outcomes in GDM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.